EDIT vs MGTX
EDIT: A gene editing pioneer leveraging CRISPR technology to develop in vivo, one-time therapies for serious genetic diseases. MGTX: MeiraGTx is a vertically integrated genetic medicine company developing a pipeline of gene therapies and a unique riboswitch platform for dose-responsive, oral-small-molecule control of gene expression.
Side-by-side fundamentals
| Metric | EDIT | MGTX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $2.58 | $9.97 | |
| Market cap | $396M | $958M | |
| P/E as of 2026-10-20 | n/a | 11.46 | |
| Net margin FY2025, SEC XBRL | -395.0% | -140.3% | MGTX higher |
| Operating margin FY2025, SEC XBRL | -394.9% | -130.2% | MGTX higher |
| ROE FY2025, SEC XBRL | -586.6% | n/a | |
| ROA FY2025, SEC XBRL | -85.8% | -46.7% | MGTX higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.53 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +25.4% | +144.6% | MGTX higher |
| Revenue CAGR (3y) SEC XBRL | +27.1% | +141.0% | MGTX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.24 | 1.17 | |
| 1-year return as of 2026-10-20 close | -37.7% | +21.0% | MGTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.